Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Articles

Page Path
HOME > Cancer Res Treat > Volume 52(4); 2020 > Article
Case Report EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, MD1, Bo Mi Ku, PhD2, Hyun Ae Jung, MD, PhD1, Jong-Mu Sun, MD, PhD1, Jin Seok Ahn, MD, PhD1, Se-Hoon Lee, MD, PhD1, Keunchil Park, MD, PhD1, Myung-Ju Ahn, MD, PhD1,
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2020;52(4):1288-1290.
DOI: https://doi.org/10.4143/crt.2020.278
Published online: June 22, 2020

1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence: Myung-Ju Ahn, MD, PhD Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: 82-2-3410-3438 Fax: 82-2-3410-1754 Email: silkahn@skku.edu
• Received: April 5, 2020   • Accepted: June 19, 2020

Copyright © 2020 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 8,164 Views
  • 333 Download
  • 20 Web of Science
  • 8 Crossref
  • 20 Scopus
prev next
  • The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.
Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation treated with either a first- or second-generation tyrosine kinase inhibitor (TKI) can experience treatment failure, most commonly by acquiring an additional genomic alteration in EGFR T790M [1]. Lazertinib (YH25448) is a potent irreversible third-generation EGFR TKI that targets both T790M and activating EGFR mutation with high penetration to the blood-brain barrier. Lazertinib showed promising anti-tumor efficacy with a 57% overall response rate and 9.7-month median progression-free survival in EGFR T790M-positive patients [2]. However, there is no previous report showing the mechanism of tumor resistance acquisition to lazertinib. In this case report, we conducted deep-targeted sequencing of resistant tumor samples and established patient-derived cell lines (PDC) from a patient treated with lazertinib to elucidate the underlying genomic alteration associated with resistance.
A 38-year-old current male smoker presented with stage 4, cT1bN3M1b, NSCLC adenocarcinoma. Informed consent was received under supervision of institutional review board (SMC 2011-10-054-034). The patient was shown to harbor an EGFR exon 19 deletion using real-time polymerase chain reaction from the initial biopsy sample obtained from the mediastinal lymph node. Afatinib was administered as a first-line treatment and showed very good partial response with 7.1 months of progression-free survival. After first-line EGFR TKI failure, a second biopsy from the newly progressed metastatic lymph node showed acquired EGFR T790M mutation. As a subsequent treatment, the patient received lazertinib as a part of a clinical trial (NCT03046992, YH25448-201). However, after 6.2 months of partial response to lazertinib, the patient developed malignant ascites, suggesting peritoneal seeding due to resistance.
Deep-targeted sequencing (CancerSCAN [3]) of ascites samples demonstrated acquired EGFR C797S mutation in cis, variant allele frequency (VAF) of 9.4%, EGFR T790M (VAF of 3.5%), and EGFR exon 19 deletion (VAF 9.2%) (Fig. 1A). PDCs established from the same ascites sample showed EGFR exon 19 deletion (Fig. 1B). Cell viability of PDCs showed resistance to first- and third-generation EGFR TKIs including erlotinib, gefitinib, lazertinib, and osimertinib or the c-Met inhibitor savolitinib (Fig. 1C).
Diverse resistance mechanisms to third-generation EGFR TKI have been reported including loss of T790M, acquisition of EGFR C797S mutation, c-Met amplification, activation of other bypass tract, or small cell lung cancer transformation. Among them, EGFR C797S/T790M mutation is the most frequently observed, accounting for 20%-30% of cases. It is of note that tumors acquiring an additional mutation of EGFR C797X maintain the original EGFR T790M mutation [4]. In this report, we present the first clinical case of new EGFR C797S/T790M mutation in a patient who failed lazertinib. Further validation with a large number of patients and new treatment strategies to overcome this resistance mutation are warranted.

Conflict of interest relevant to this article was not reported.

Fig. 1.
(A) Target sequencing in samples from lazertinib-resistant malignant ascites. Integrative genomic viewer of sample showing additional epidermal growth factor receptor (EGFR) C797S cis mutation. (B) Western blot of patient-derived cell line (PDC) samples. (C) Cell viability analyses conducted in samples after exposure to tyrosine kinase inhibitor for 72 hours. SNV, single nucleotide variant; INDEL, insertion/deletion; EpCAM, epithelial cell adhesion molecule.
crt-2020-278f1.jpg
  • 1. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.ArticlePubMedPMC
  • 2. Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20:1681–90. ArticlePubMed
  • 3. Shin HT, Choi YL, Yun JW, Kim NK, Kim SY, Jeon HJ, et al. Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nat Commun. 2017;8:1377.ArticlePubMedPMCPDF
  • 4. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4:1527–34. ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Research Advances of Small Molecule EGFR-TKIs in NSCLC
      亚南 胡
      Pharmacy Information.2024; 13(01): 1.     CrossRef
    • An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
      Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Ekta Singh, Abhishek Ghara, Lalmohan Maji, Sindhuja Sengupta, Ganesh Andhale
      Journal of Biomolecular Structure and Dynamics.2024; 42(3): 1564.     CrossRef
    • The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
      Yu Zhang, Chengmeng Wang, Jing Zhao, Meng Wang
      Thoracic Cancer.2024; 15(23): 1757.     CrossRef
    • Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
      Yue Fang, Qiankun Zhang, Weimin Wang, Juanjuan Tong, Xialin Li
      Frontiers in Oncology.2023;[Epub]     CrossRef
    • A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship
      Tanuja T. Yadav, Gulam Moin Shaikh, Maushmi S. Kumar, Meena Chintamaneni, Mayur YC
      Frontiers in Chemistry.2022;[Epub]     CrossRef
    • Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
      David E. Heppner, Florian Wittlinger, Tyler S. Beyett, Tatiana Shaurova, Daniel A. Urul, Brian Buckley, Calvin D. Pham, Ilse K. Schaeffner, Bo Yang, Blessing C. Ogboo, Earl W. May, Erik M. Schaefer, Michael J. Eck, Stefan A. Laufer, Pamela A. Hershberger
      ACS Medicinal Chemistry Letters.2022; 13(12): 1856.     CrossRef
    • Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
      Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong
      Pharmaceuticals.2021; 14(6): 589.     CrossRef
    • Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
      Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
      BMB Reports.2021; 54(7): 386.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
      Cancer Res Treat. 2020;52(4):1288-1290.   Published online June 22, 2020
      Close
    • XML DownloadXML Download
    EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
    Image
    Fig. 1. (A) Target sequencing in samples from lazertinib-resistant malignant ascites. Integrative genomic viewer of sample showing additional epidermal growth factor receptor (EGFR) C797S cis mutation. (B) Western blot of patient-derived cell line (PDC) samples. (C) Cell viability analyses conducted in samples after exposure to tyrosine kinase inhibitor for 72 hours. SNV, single nucleotide variant; INDEL, insertion/deletion; EpCAM, epithelial cell adhesion molecule.
    EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

    Cancer Res Treat : Cancer Research and Treatment
    Close layer
    TOP